FDA: Enzon's Abelcet makes unsubstantiated superiority claims

Share this article:
A flash card for Enzon's Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says. A warning letter says the claims raise concerns because they suggest it is more effective than  demonstrated and encourage its use before other options, even though it is a second-line agent.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions